SCHEMBL256715

SCHEMBL256715

COC(=O)c1ccc(I)cc1O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 6/20 0.67
CA1 P00915 6/20 0.67
CA2 P00918 6/20 0.67
CA7 P43166 6/20 0.67
CA9 Q16790 6/20 0.67
CA14 Q9ULX7 6/20 0.67
PDK2 Q15119 1/20 0.67
PDK4 Q16654 1/20 0.67
GAA P10253 2/20 0.62
SMN1; SMN2 Q16637 2/20 0.57
LMNA P02545 2/20 0.55
TSHR P16473 1/20 0.55
MYC P01106 1/20 0.54
EGFR P00533 1/20 0.47
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
MAPT P10636 2/20 0.44
HPGD P15428 2/20 0.44
HSD17B10 Q99714 2/20 0.44
GLA P06280 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29993089 1.00 CA12 (0.67) CA12CA1CA2CA7CA9
SCHEMBL1004955 0.85 CA12 (0.67) CA12CA1CA2CA7CA9
SCHEMBL15326189 0.84 CA12 (0.50) CA12CA1CA2CA7CA9
SCHEMBL31585831 0.84 CA12 (0.50) CA12CA1CA2CA7CA9
SCHEMBL2351916 0.81 KDM4E (0.49) CA12CA1CA2CA7CA9
SCHEMBL27297567 0.80 GABRG2 (0.44) CA12CA1CA2CA7CA9
SCHEMBL6031436 0.80 CA12 (0.70) CA12CA1CA2CA7CA9
Methyl 2,4-Dihydroxybenzoate SCHEMBL382883 0.80 CA12 (1.00) CA12CA1CA2CA7CA9
SCHEMBL8200161 0.80 CA12 (0.71) CA12CA1CA2CA7CA9
Methyl 2,4-Dihydroxybenzoate SCHEMBL30917273 0.80 CA12 (1.00) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577217-B2 15-PGDH inhibitor KYORIN PHARMACEUTICAL CO., LTD. (JP) 2026-03-17 US disclosed
EP-4652159-A1 INHIBITORS OF KIF18A AND USES THEREOF Insilico Medicine IP Limited (HK) 2025-11-26 EP disclosed
US-20250340569-A1 INHIBITORS OF KIF18A AND USES THEREOF INSILICO MEDICINE IP LTD (CN) 2025-11-06 US disclosed
US-20250289780-A1 N,N'-DIPHENYL-4,4'-BIPHENYLDICARBOXAMIDE ANALOGS AND THEIR USE IN CANCER TREATMENT BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2025-09-18 US disclosed
WO-2025149498-A1 BENZYLPIPERIDINE DERIVATIVES AS TRP4 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES ASTRAZENECA AB (SE) 2025-07-17 WO disclosed
WO-2025106910-A1 DEGRADER MOLECULES TARGETING ANDROGEN RECEPTOR FLARE THERAPEUTICS INC. (US) 2025-05-22 WO disclosed
US-20250114466-A1 ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES BYONDIS B.V. (NL) 2025-04-10 US disclosed
WO-2025053850-A1 COVALENT KRAS-BINDING COMPOUNDS FOR MEDICAL TREATMENT HYKU BIOSCIENCES INC. (US) 2025-03-13 WO disclosed
CN-119059895-A Preparation method of 2,2 '-dihydroxybiphenyl-4, 4' -dicarboxylic acid 黑龙江省科学院石油化学研究院 2024-12-03 CN disclosed
EP-4457229-A1 ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES Byondis B.V. (NL) 2024-11-06 EP disclosed
US-5798354-A COSMETIC, THERAPY CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 1998-08-25 US disclosed
WO-1998029119-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1998-07-09 WO disclosed
US-5766610-A USEFUL FOR TREATMENT OF MAMMALIAN SKIN AND HAIR, RHEUMATISM, RESIPIRATORY SYSTEM DISORDER, CARDIOVASCULAR AND VISION DISORDERS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 1998-06-16 US disclosed
US-5763450-A BACTERICIDES; TREATMENT OF INFECTIOUS DISEASES HOFFMANN-LA ROCHE INC. (US) 1998-06-09 US disclosed
US-5723499-A Polycyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof C.I.R.D. GALDERMA (FR) 1998-03-03 US disclosed
US-5716624-A USEFUL FOR TREATING DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR, OPTHALMOLOGICAL DISORDERS, AS WELL AS MAMMALIAN SKIN AND HAIR CONDITIONS/DISORDERS C.I.R.D. GALDERMA (FR) 1998-02-10 US disclosed
CN-1166831-A Novel benzyl pyrimidines HOFFMANN LA ROCHE (CH) 1997-12-03 CN disclosed
EP-0793656-A1 NOVEL BENZYL PYRIMIDINES F. HOFFMANN-LA ROCHE AG (CH) 1997-09-10 EP disclosed
US-5574036-A Adamantyl-substituted polycyclic acetylene compounds and pharmaceutical/cosmetic compositions comprised thereof CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 1996-11-12 US disclosed
WO-1996016046-A2 NOVEL BENZYL PYRIMIDINES F. HOFFMANN-LA ROCHE AG (CH) 1996-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250114466-A1 ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES DHFR, FOLR1, MTHFD2 CA12 1260/4885CA1 2964/4885CA2 4161/4885
US-20250289780-A1 N,N'-DIPHENYL-4,4'-BIPHENYLDICARBOXAMIDE ANALOGS AND THEIR USE IN CANCER TREATMENT NCOR1, NR1H4, NR1I2 CA12 2884/4885CA1 2457/4885CA2 1799/4885
US-12577217-B2 15-PGDH inhibitor PTGDR, ADH1A, ADRA1A CA12 2443/4885CA1 1410/4885CA2 1125/4885
US-20250340569-A1 INHIBITORS OF KIF18A AND USES THEREOF KIF18A, KIF18B, KIF2C CA12 4387/4885CA1 4262/4885CA2 4243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.